Lys276

Site Information
IRSITAAkYREKQQV SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 11322582
Available spectra: 1 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 8 , 9 , 10 )
Disease tissue studied:	leukemia ( 8 , 9 ) , chronic myelogenous leukemia ( 8 , 9 ) , lung cancer ( 1 , 2 , 3 ) , non-small cell lung cancer ( 1 , 2 , 3 , 4 , 5 , 6 ) , non-small cell lung adenocarcinoma ( 1 , 2 , 3 , 5 ) , non-small cell large cell lung carcinoma ( 1 , 3 ) , non-small cell squamous cell lung carcinoma ( 6 )
Relevant cell line - cell type - tissue:	A549 (pulmonary) ( 2 ) , HCC78 (pulmonary) ( 1 ) , Jurkat (T lymphocyte) ( 10 ) , K562 (erythroid) ( 8 , 9 ) , lung ( 1 , 2 , 3 ) , MV4-11 (macrophage) ( 10 ) , NCI-H1299 (pulmonary) ( 3 ) , NCI-H1355 (pulmonary) ( 2 ) , NCI-H1703 (squamous) ( 6 ) , NCI-H1734 (pulmonary) ( 3 ) , NCI-H1781 (pulmonary) ( 1 ) , NCI-H1792 (pulmonary) ( 2 ) , NCI-H1944 (pulmonary) ( 3 ) , NCI-H2228 (pulmonary) ( 1 , 5 ) , NCI-H23 (pulmonary) ( 2 ) , NCI-H3122 (pulmonary) ( 1 , 4 ) , NCI-H358 (pulmonary) ( 3 ) , NCI-H441 (pulmonary) ( 2 ) , NCI-H460 (pulmonary) ( 3 ) , NCI-H661 (pulmonary) ( 1 )

References
1	Rikova K (2013) CST Curation Set: 20219; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
2	Rikova K (2013) CST Curation Set: 20215; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
3	Rikova K (2013) CST Curation Set: 20216; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
4	Rikova K (2013) CST Curation Set: 18855; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
5	Rikova K (2013) CST Curation Set: 18854; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
6	Rikova K (2012) CST Curation Set: 16032; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
7	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
8	Moritz A (2010) CST Curation Set: 9818; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
9	Moritz A (2010) CST Curation Set: 9817; Year: 2010; Biosample/Treatment: cell line, K-562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Curated Info
10	Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40 19608861 Curated Info